Author + information
- Received December 21, 1987
- Revision received March 23, 1988
- Accepted May 23, 1988
- Published online October 1, 1988.
- Elliott M. Antman, MD, FACC∗,
- Andrew D. Beamer, MD1,
- Catherine Cantillon, RN,
- Noreen McGowan, RN,
- Lee Goldman, MD, FACC and
- Peter L. Friedman, MD, PhD
- ↵∗Address for reprints: Elliott M. Antman, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115.
Sixty patients who had recurrent episodes of symptomatic atrial fibrillation or flutter, or both, and who had failed one to five prior drug trials were treated with open label oral propafenone hydrochloride. On a mean maximal tolerated dose of 795 ± 180 mg/day, actuarial estimates of the percent of individuals free of recurrences of symptomatic atrial fibrillation/flutter during propafenone treatment were: 1 month, 54%; 3 months, 44% and 6 months, 40%. No individual baseline characteristic achieved statistical significance as a correlate of poor response to propafenone. Drug-related adverse reactions were reported in 22% of patients but were severe enough to require termination of propafenone in only 5%.
Thus, oral propafenone is a useful and well tolerated drug for long-term suppression of symptomatic recurrences of atrial fibrillation/flutter despite a history of unresponsiveness to prior antiarrhythmic drug treatment.
↵1 Dr. Beamer is supported by a National Research Service Award (1-T32-HL07604) from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland and by a grant to the Program in Clinical Effectiveness from the W.K. Kellogg Foundation, Battle Creek, Michigan.
☆ This work was presented in part at the 60th Scientific Sessions of the American Heart Association, Anaheim, California.
- Received December 21, 1987.
- Revision received March 23, 1988.
- Accepted May 23, 1988.